drugset / Trial / NCT02652416

Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers

NCT02652416

Phase 1 Completed 72 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Safety and tolerability of BI 1026706 in healthy Chinese and Japanese male subjects following oral administration of single rising doses (SRD) followed by multiple rising doses (MRD)

Timeline

Start
2016-09-16
Primary completion
2016-12-09
Completion
2016-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1026706 Unknown Oral

Indications

No indication recorded.